日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma

多发性骨髓瘤中针对GPRC5D靶向T细胞衔接器的多模式抗原逃逸

Lee, Holly; Ahn, Sungwoo; Gonzales, Gerone A; Leblay, Noemie; Barakat, Elie; Greening, Dylan; Colarusso, Pina; Canton, Johnathan; Benaoudia, Sacha; Hasheminasabgorji, Elham; Poorebrahim, Mansour; Jung, David; Truger, Marietta; Jeong, Jihong; Riedhammer, Christine; Einsele, Hermann; Kortüm, K Martin; Eckmann, Jan; Somandin, Jitka; Engel, Sara-Sheena; Boise, Lawrence H; Frenking, Jan Hendrik; Weinhold, Niels; Taouxi, Konstantina; Kastritis, Efstathios; Skerget, Sheri; Vishwamitra, Deeksha; Cho, Yunje; Maura, Francesco; Raab, Marc S; Corre, Jill; Rasche, Leo; Avet-Loiseau, Hervé; Neri, Paola; Bahlis, Nizar J

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

在 t(11;14) 阳性复发/难治性多发性骨髓瘤中,维奈托克-地塞米松与泊马度胺-地塞米松的疗效比较:随机 III 期 CANOVA 研究的主要结果

Popat, Rakesh; Beksac, Meral; Dimopoulos, Meletios A; Gatt, Moshe E; Gay, Francesca; Jo, Jae-Cheol; Kapoor, Prashant; Katodritou, Eirini; Kortüm, K Martin; Ling, Silvia; Nagarajan, Chandramouli; Suzuki, Kenshi; Qiu, Lugui; Onishi, Maika; Ku, Grace; Dail, Monique; Mukherjee, Nabanita; Ross, Jeremy A; Badawi, Mohamed Ali; Fusco, Mary Jean; Dobkowska, Edyta; Arriola, Emma; Bueno, Orlando F; Bahlis, Nizar J; Iida, Shinsuke; Moreau, Philippe; Valent, Jason; Mateos, María-Victoria

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

七抗耐药性骨髓瘤的演变涉及 CD38、BCMA 和 GPRC5D 的依次丢失。

Riedhammer, C; Truger, M; Lee, H; Leypoldt, L B; Meggendorfer, M; Hutter, S; Müller, H; Mersi, J; Kadel, S K; Buchwald, T; Kosch, R; Helal, M; Afrin, N; Rosenwald, A; Gerhard-Hartmann, E; Brioli, A; Krönke, J; Haferlach, T; Haferlach, C; Weisel, K C; Neri, P; Einsele, H; Kortüm, K M; Waldschmidt, J M; Bahlis, N; Weinhold, N; Rasche, L

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

在接受过三类药物治疗的复发/难治性多发性骨髓瘤患者中,Talquetamab 与真实世界医生选择的治疗方案的疗效比较:MonumentTAL-1 与 LocoMMotion/MoMMent 研究的最新分析

Einsele, Hermann; Moreau, Philippe; Bahlis, Nizar; Bhutani, Manisha; Vincent, Laure; Karlin, Lionel; Perrot, Aurore; Goldschmidt, Hartmut; van de Donk, Niels W C J; Ocio, Enrique M; Martínez López, Joaquín; Rodríguez-Otero, Paula; Dytfeld, Dominik; Jakubowiak, Andrzej; Schinke, Carolina; Besemer, Britta; Anguille, Sébastien; Manier, Salomon; Rasche, Leo; Teipel, Raphael; Scheid, Christof; Pawlyn, Charlotte; Cavo, Michele; Diels, Joris; Ghilotti, Francesca; Lau, Bonnie W; Renaud, Thomas; Orel, Oleksiy; Ong, Fenny; Ramos, Diogo F; Ammann, Eric; Parekh, Trilok; Albrecht, Claire; Weisel, Katja; Mateos, María-Victoria

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma

美齐度胺联合硼替佐米可破坏细胞周期,并在多发性骨髓瘤中产生更优的抗肿瘤作用。

Bjorklund, Chad C; Larrayoz, Marta; Kang, Jian; Chiu, Hsiling; Shtraizent, Natasha; Wu, Lei; Li, Shirong; Hsu, Chih-Chao; Zhao, Junfei; Amatangelo, Michael; Chow, Tracy T; Wollerman, Krista; Singh, Ram Kumar; Sridhara, Sneha; Dudhgaonkar, Shailesh; Subramanyam, Prakash; Ghosh, Kaushik; Richardson, Paul G; Bahlis, Nizar J; Thakurta, Anjan; Martinez-Climent, Jose A; Gandhi, Anita K; Hagner, Patrick R

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

作者更正:达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松治疗不适合移植或因故推迟移植的新诊断多发性骨髓瘤:随机3期CEPHEUS试验

Usmani, Saad Z; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J; Venner, Christopher P; Braunstein, Marc; Pour, Ludek; Martí, Josep M; Basu, Supratik; Cohen, Yael C; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Ahmadi, Tahamtan; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Zweegman, Sonja

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松治疗不适合移植或因故推迟移植的新诊断多发性骨髓瘤:一项随机3期CEPHEUS试验

Usmani, Saad Z; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J; Venner, Christopher P; Braunstein, Marc; Pour, Ludek; Martí, Josep M; Basu, Supratik; Cohen, Yael C; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Ahmadi, Tahamtan; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Zweegman, Sonja

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

双等位基因抗原逃逸是多发性骨髓瘤对抗CD38抗体产生耐药性的机制之一。

Benjamin Diamond ,Linda Baughn ,Mansour Poorebrahim ,Alexandra M Poos ,Holly Lee ,Marcella Kaddoura ,J Erin Wiedmeier-Nutor ,Michael Durante ,Gregory Otteson ,Dragan Jevremovic ,Hongwei Tang ,Stefan Fröhling ,Marc A Baertsch ,Marios Papadimitriou ,Bachisio Ziccheddu ,Tomas Jelinek ,Cendrine Lemoine ,Alexey Rak ,Damian J Green ,Ola Landgren ,Paola Neri ,Leif Bergsagel ,Esteban Braggio ,Shaji Kumar ,Marc S Raab ,Rafael Fonseca ,Nizar Bahlis ,Niels Weinhold ,Francesco Maura

The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3

降低elranatamab给药频率对复发或难治性多发性骨髓瘤患者患者报告结局的影响:MagnetisMM-3研究结果

Bahlis, Nizar J; Nooka, Ajay K; DiBonaventura, Marco; Sullivan, Sharon T; Chaudhary, Mohammad A; Aydin, Didem; Mohty, Mohamad

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

达雷妥尤单抗/来那度胺/地塞米松治疗不适合移植的新诊断多发性骨髓瘤:MAIA长期疗效

Facon, Thierry; Moreau, Philippe; Weisel, Katja; Goldschmidt, Hartmut; Usmani, Saad Z; Chari, Ajai; Plesner, Torben; Orlowski, Robert Z; Bahlis, Nizar; Basu, Supratik; Hulin, Cyrille; Quach, Hang; O'Dwyer, Michael; Perrot, Aurore; Jacquet, Caroline; Venner, Christopher P; Raje, Noopur; Tiab, Mourad; Macro, Margaret; Frenzel, Laurent; Leleu, Xavier; Cook, Gordon; Wang, George; Pei, Huiling; Krevvata, Maria; Carson, Robin; Borgsten, Fredrik; Kumar, Shaji K